# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed fo...
HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleo...
Key Findings: HBsAg ≤ LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of ...
https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0.pdf
Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0...